Scholarlink

<p>Keloids are persistent fibroproliferative scars with an incompletely understood pathogenesis, traditionally linked to pathways such as TGF-β signaling and chronic inflammation. This review synthesizes recent literature focusing on the emerging roles of metabolic reprogramming and ferroptosis resistance in keloid fibroblasts. Recent studies highlight the convergence of these two processes as central factors sustaining the persistence and therapeutic resistance of these cells. Keloid fibroblasts exhibit cancer-like metabolic reprogramming, marked by a shift toward aerobic glycolysis, mitochondrial dysfunction, and disrupted lipid metabolism. This metabolic reorganization not only reflects the fibrotic process but also serves as a key driver of the fibroblasts’ hyperproliferative, invasive, and matrix-producing characteristics. Concurrently, these fibroblasts display significant resistance to ferroptosis, an iron-dependent regulated cell death mechanism, acting as a critical survival strategy. Mechanistically, enhanced glycolysis supplies the reducing equivalents required to sustain the GPX4 antioxidant system, thereby preventing ferroptosis by neutralizing lipid peroxidation. Recognizing this integrated metabolic-ferroptotic axis shifts the therapeutic paradigm from symptomatic management to targeted, mechanism-based strategies. Interventions targeting critical nodes, such as glycolytic enzymes, or inducing ferroptosis with agents like ALA-PDT, present promising approaches to dismantle the survival advantages of keloid fibroblasts. These novel strategies offer the potential for more durable disease control, providing a foundation to overcome current translational challenges in drug delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic reprogramming and ferroptosis in keloid pathogenesis: new insights for targeted therapy

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Dongxian Lin,
  • Li Duan,
  • Yuanyuan Xu,
  • Shunbing Lu,
  • Chenhao Ma,
  • Yuchen Zhang,
  • Bincheng Wang,
  • Yue Liu,
  • Shanbaga Zhao,
  • Lianzhao Wang

摘要

Keloids are persistent fibroproliferative scars with an incompletely understood pathogenesis, traditionally linked to pathways such as TGF-β signaling and chronic inflammation. This review synthesizes recent literature focusing on the emerging roles of metabolic reprogramming and ferroptosis resistance in keloid fibroblasts. Recent studies highlight the convergence of these two processes as central factors sustaining the persistence and therapeutic resistance of these cells. Keloid fibroblasts exhibit cancer-like metabolic reprogramming, marked by a shift toward aerobic glycolysis, mitochondrial dysfunction, and disrupted lipid metabolism. This metabolic reorganization not only reflects the fibrotic process but also serves as a key driver of the fibroblasts’ hyperproliferative, invasive, and matrix-producing characteristics. Concurrently, these fibroblasts display significant resistance to ferroptosis, an iron-dependent regulated cell death mechanism, acting as a critical survival strategy. Mechanistically, enhanced glycolysis supplies the reducing equivalents required to sustain the GPX4 antioxidant system, thereby preventing ferroptosis by neutralizing lipid peroxidation. Recognizing this integrated metabolic-ferroptotic axis shifts the therapeutic paradigm from symptomatic management to targeted, mechanism-based strategies. Interventions targeting critical nodes, such as glycolytic enzymes, or inducing ferroptosis with agents like ALA-PDT, present promising approaches to dismantle the survival advantages of keloid fibroblasts. These novel strategies offer the potential for more durable disease control, providing a foundation to overcome current translational challenges in drug delivery.